Dialysis: How Machines Replace Failing Kidneys

Replacing an Organ That Filters 180 Liters Daily

Healthy kidneys filter approximately 180 liters of blood plasma every 24 hours, reabsorbing 99% of the filtrate and excreting the remainder as roughly 1.5 to 2 liters of urine. When kidney function drops below 10–15% of normal—a condition called end-stage renal disease (ESRD)—waste products accumulate to life-threatening levels within days. Without dialysis or transplantation, ESRD is uniformly fatal. Globally, over 3.4 million people depend on dialysis to survive.

Dialysis does not replicate all kidney functions. It removes waste products and excess fluid but cannot produce erythropoietin (which stimulates red blood cell production), activate vitamin D, or regulate long-term calcium-phosphorus balance with the precision of a healthy kidney. Patients on dialysis require supplemental medications to compensate for these missing functions.

Hemodialysis: Filtering Blood Through a Machine

Hemodialysis routes the patient’s blood through an external circuit containing a dialyzer—a device roughly the size of a large water bottle packed with thousands of hollow, semi-permeable fibers. Blood flows through the fiber interiors. A specially formulated solution called dialysate flows in the opposite direction around the fibers’ exteriors. Waste products (urea, creatinine, potassium, phosphorus) cross the fiber membrane from blood into dialysate by diffusion. Excess water is removed by applying a pressure gradient—a process called ultrafiltration.

Standard hemodialysis requires three sessions per week, each lasting 3 to 5 hours. Most patients receive treatment in outpatient dialysis centers, though home hemodialysis is available and growing. Vascular access is achieved through an arteriovenous fistula (surgically connecting an artery to a vein in the arm), an arteriovenous graft, or a central venous catheter.

Vascular Access: The Lifeline

An arteriovenous (AV) fistula is the preferred access method. The connection causes the vein to enlarge and develop thicker walls, making it suitable for repeated needle insertion. Fistulas have the lowest infection rates and longest functional lifespans among access types.

• AV fistula: lowest complication rate, requires 6–8 weeks to mature before use
• AV graft: synthetic tube connecting artery to vein, usable within 2–4 weeks, higher infection risk
• Central venous catheter: used for urgent access, highest infection and clotting rates
• Access-related complications are the leading cause of hospitalization in hemodialysis patients

Peritoneal Dialysis: Using the Body’s Own Membrane

Peritoneal dialysis (PD) uses the peritoneum—the membrane lining the abdominal cavity—as the dialysis membrane. A catheter implanted through the abdominal wall allows dialysate to flow into the peritoneal cavity. Waste products and excess fluid cross from peritoneal capillaries into the dialysate over a dwell period of 4 to 8 hours. The patient then drains the used solution and replaces it with fresh dialysate.

Peritoneal dialysis offers significant lifestyle advantages. Patients perform treatments at home without needles or blood circuits. Travel is easier. Employment rates among PD patients are higher than among hemodialysis patients. However, the peritoneal membrane gradually loses efficiency over years, and peritonitis (infection of the peritoneal cavity) remains a persistent risk.

Outcomes and Survival

Five-year survival rates for dialysis patients vary by country, age, and comorbidities. In the United States, the overall five-year survival rate for ESRD patients on dialysis is approximately 35–40%. Cardiovascular disease is the leading cause of death, accounting for roughly 40% of dialysis patient mortality. The annual mortality rate for hemodialysis patients in the U.S. exceeds 15%.

• Kidney transplant recipients have significantly better survival: 5-year graft survival exceeds 85% for deceased-donor transplants
• The kidney transplant waiting list in the U.S. exceeds 90,000 patients, with a median wait time of 3–5 years
• Japan has the highest dialysis survival rates globally, attributed to longer treatment sessions and dietary compliance
• Nocturnal hemodialysis (6–8 hours overnight) shows improved outcomes compared to conventional 4-hour sessions

Global Access and Cost

Dialysis costs vary enormously. In the United States, Medicare covers ESRD treatment regardless of age—a unique provision established by Congress in 1972. Annual per-patient cost exceeds $90,000. ESRD patients represent less than 1% of the Medicare population but account for approximately 7% of Medicare spending.

In low-income countries, most ESRD patients have no access to dialysis. An estimated 2.3 to 7.1 million people die annually from untreated kidney failure, primarily in sub-Saharan Africa and South Asia. The disparity is stark: dialysis prevalence exceeds 2,000 per million population in Japan and Taiwan but falls below 100 per million in most African countries.

Toward Artificial and Bioartificial Kidneys

Research into wearable and implantable artificial kidneys aims to free patients from fixed treatment schedules. The Kidney Project, funded by the U.S. National Institutes of Health, is developing a surgically implantable device combining silicon nanopore membranes with living kidney cells. Early prototypes have demonstrated waste clearance in animal models. A compact, wearable hemodialysis device could allow continuous, low-flow dialysis during daily activities. Neither technology has reached clinical trials in humans as of early 2026, but the goal remains the same: to replace an organ’s function without tethering a patient to a machine three times per week.

This article is for informational purposes only. Consult a qualified professional.